TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03259919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
Study: NCT00963872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood unit with C3a fragment
Description: On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood unit with C3a fragment
Description: On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unmanipulated UCB Unit
Description: On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unmanipulated UCB Unit
Description: On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
Study: NCT02115087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided rectus sheath block
Description: the application of rectus sheath block with ultrasound guidance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT03949517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga RM2
Description: Radioactive agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga RM2
Description: Radioactive agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: Radioactive agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga PSMA11
Description: Radioactive agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational software and coils in PET/MR Scan
Description: Investigational software and coils in PET/MR Scan by General Electric Healthcare

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational software and coils in PET/MR Scan
Description: Investigational software and coils in PET/MR Scan by General Electric Healthcare

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
Study: NCT04039243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Being Brave
Description: Up to 12 weekly sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: Parents receive educational materials about helping children overcome shyness and fear
Study: NCT00561990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nimotuzumab
Study: NCT01777477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Addition of Chloroquine to Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT02916485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold
Description: Percutaneous coronary intervention (PCI)
Study: NCT00485173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate
Description: All patients enrolled in this study will receive the investigational device.
Study: NCT04193735

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans after a liquid meal
Description: Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans after a liquid meal
Description: Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times
Study: NCT01915641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
Study: NCT02152462

Intervention type: OTHER
Group type: OTHER
Intervention: Exergaming
Description: The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
Study: NCT01505361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius PS2
Description: 9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Excipient (milk powder)
Description: 100 mg/once a day from 30 week of pregnancy until birth
Study: NCT04091802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interdental papilla reconstruction with L-PRF
Description: interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interdental papilla reconstruction with L-PRF
Description: interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
Study: NCT03012659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive Counseling Training
Description: Intervention sites will receive:~1. In person training: All staff at an intervention health center will participate in a one-day counseling training.~2. On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~3. Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance.
Study: NCT02555319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Pulmonary Valve (TPV)
Description: Transcatheter Pulmonary Valve Replacement
Study: NCT03239977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Social Intelligence Training
Description: The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control (AC)
Description: A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
Study: NCT04233138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUPPORT online platform for people with type 1 diabetes
Description: All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform.
Study: NCT00546910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of placebo have to be taken once daily in the morning, with or without food.
Study: NCT04490226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Hydroxybutyrate as Ca-Mg-salt, active
Description: 24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Hydroxybutyrate as Ca-Mg-salt, active
Description: 24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Hydroxybutyrate as Ca-Mg-salt, active
Description: 24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Hydroxybutyrate as Ca-Mg-salt, active
Description: 24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active
Description: 24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
Study: NCT02206542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper limb rehabilitation robot
Description: Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Study: NCT03516019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekend notices
Description: notifications sent on Saturday
Study: NCT02206542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Study: NCT03212131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: 3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: 3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: 3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
Study: NCT04648423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: solution for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for oral administration
Study: NCT03965663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro-tactile Feedback
Description: The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibro-tactile Feedback
Description: The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.
Study: NCT01519622

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire to be distributed among sick elderly in the community
Study: NCT02249286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Centered Nutrition Counseling
Description: The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: the control will only receive the agriculture extension and the existing health and nutrition education in the area
Study: NCT03665350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile.
Study: NCT03493425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT02206542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Study: NCT03691181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation
Description: monitoring with the use of the Life2000 Ventilation System for a period of six months
Study: NCT02615314

Intervention type: PROCEDURE
Intervention: Particle re-positioning maneuver
Description: Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.

Intervention type: PROCEDURE
Intervention: Particle re-positioning maneuver
Description: Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
Study: NCT00808990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioFemale
Description: BioFemale 6 months.
Study: NCT02902432

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endostar
Description: The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
Study: NCT04490226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active
Description: 24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active
Description: 24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active
Description: 24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting, active
Description: 36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
Study: NCT01872819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antitumor drug screening assay
Description: Undergo high throughput drug sensitivity assay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Patients receive 1 of 160 possible interventions

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological therapy
Description: Patients receive 1 of 160 possible interventions
Study: NCT03493425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image Guided Radiation Therapy
Description: Undergo image guided IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo image guided IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo image guided IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo image guided IMRT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04490226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting, active
Description: 36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting, active
Description: 36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting, active
Description: 36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting, inactive
Description: 36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting, inactive
Description: 36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later.
Study: NCT00243399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
Study: NCT03646006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 mL (5mg/mL)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 10 mL normal saline